All In Biotech

Drug Trial Radar · NCT04972396

Pemvidutide (ALT-801) DDI Study in Healthy Volunteers

An Open-label Study of the Effect of ALT-801 on the Pharmacokinetics of Metformin, Warfarin, Atorvastatin, Digoxin, and the Combined Oral Contraceptive Ethinylestradiol/Levonorgestrel in Healthy Volunteers

Last checked: Nov 19, 2026Latest source record: Jun 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

40

Actual

Start

Sep 15, 2021

Primary completion

May 15, 2022

Study completion May 15, 2022

Sponsor

Lead sponsor
Altimmune, Inc.Industry
Sponsor type
Industry
First posted
Jul 22, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Other
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 55 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This is a Phase 1, open-label, drug-drug interaction (DDI) study of pemvidutide (ALT-801) under steady state conditions on concomitantly administered medications in healthy subjects. The study will evaluate the effect of pemvidutide on the pharmacokinetics (PK) of metformin, warfarin, atorvastatin, digoxin, and the combined oral contraceptive (COC) ethinylestradiol/levonorgestrel. The study will be conducted in 3 parts, as described below. Each part will have 2 periods in a fixed sequence, where the first period is without pemvidutide administration and the second is with pemvidutide at steady state.

Conditions

  • NASH - Nonalcoholic Steatohepatitis

Interventions

  • PemvidutideDrug

    Injected subcutaneously (SC)

  • MetforminDrug

    Taken by mouth (PO)

  • AtorvastatinDrug

    Taken by mouth (PO)

  • WarfarinDrug

    Taken by mouth (PO)

  • DigoxinDrug

    Taken by mouth (PO)

  • Ethinylestradiol and LevonorgestrelDrug

    Taken by mouth (PO)

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area Under the Plasma Concentration Versus Time Curve (AUC) of metformin and atorvastatin/warfarin and digoxin in presence of steady state ALT-801Time frame: Baseline and Day 36
  2. Area Under the Plasma Concentration Versus Time Curve (AUC) of ethinylestradiol and levonorgestrel in presence of steady state ALT-801Time frame: Baseline and Day 43

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Nucleus Network

    Brisbane, Australia

  • CMAX Clinical Research

    Adelaide, South Australia, Australia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.